Recent Company News

• 07:13 AM ET Dec 23, 2025
  

  CSPC Pharmaceutical Group receives NMPA clinical trial approval for Daratumumab Injection (HK$8.88, 0.00)

• 11:00 PM ET Dec 22, 2025
  

  StreetAccount Summary - Trading higher/lower: Asia mid-morning

• 09:57 PM ET Dec 17, 2025
  

  StreetAccount Summary - Trading higher/lower: Hong Kong mid-morning

• 08:30 AM ET Dec 19, 2025
  

  CSPC Pharmaceutical Group obtains NMPA clinical trial approval for SYH2085 tablets for treatment of influenza (HK$8.20, 0.00)

• 08:24 AM ET Dec 19, 2025
  

  CSPC Pharmaceutical Group CEO Zhang Cuilong steps down, effective 19-Dec (HK$8.20, 0.00)

• 02:52 AM ET Dec 18, 2025
  

  CSPC Megalith Biopharmaceutical reaches primary endpoints for phase III clinical trial of secukinumab injection for mild to severe plaque psoriasis (CNY 31.13, 0.00)

• 05:36 AM ET Dec 12, 2025
  

  CSPC Pharmaceutical Group receives NMPA new indication approval for irinotecan hydrochloride liposome injection (HK$7.66, 0.00)

• 12:20 AM ET Dec 12, 2025
  

  StreetAccount Summary - Hong Kong equity offerings 6-Dec to 12-Dec

• 07:59 AM ET Dec 10, 2025
  

  CSPC Innovation Pharmaceutical files for Hong Kong IPO through CITIC Securities (CNY 34.10, 0.00)